Detailed Information

Cited 94 time in webofscience Cited 98 time in scopus
Metadata Downloads

A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Authors
Song, Do SeonSong, Myeong JunBae, Si HyunChung, Woo JinJang, Jae YoungKim, Young SeokLee, Sae HwanPark, Jun YongYim, Hyung JoonCho, Sung BumPark, Soo YoungYang, Jin Mo
Issue Date
Apr-2015
Publisher
SPRINGER JAPAN KK
Keywords
Hepatic arterial infusion chemotherapy; Sorafenib; Hepatocellular carcinoma; Portal vein tumor thrombosis
Citation
JOURNAL OF GASTROENTEROLOGY, v.50, no.4, pp.445 - 454
Indexed
SCIE
SCOPUS
Journal Title
JOURNAL OF GASTROENTEROLOGY
Volume
50
Number
4
Start Page
445
End Page
454
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8020
DOI
10.1007/s00535-014-0978-3
ISSN
0944-1174
Abstract
The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib. The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p < 0.001), although there was no significant difference in the objective response rate (p = 0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5 months, p = 0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1 months, p = 0.034). In the multivariate analysis, tumor diameter (a parts per thousand yen 10 cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p = 0.002 and p = 0.010, respectively) and TTP (p = 0.017 and p = 0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p = 0.052), but not for tumor progression (p = 0.121). HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE